40 related articles for article (PubMed ID: 2455519)
1. Electron transport chain inhibition increases cellular dependence on purine transport and salvage.
Wu Z; Bezwada D; Cai F; Harris RC; Ko B; Sondhi V; Pan C; Vu HS; Nguyen PT; Faubert B; Cai L; Chen H; Martin-Sandoval M; Do D; Gu W; Zhang Y; Zhang Y; Brooks B; Kelekar S; Zacharias LG; Oaxaca KC; Patricio JS; Mathews TP; Garcia-Bermudez J; Ni M; DeBerardinis RJ
Cell Metab; 2024 Jun; ():. PubMed ID: 38876105
[TBL] [Abstract][Full Text] [Related]
2. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations.
Toksvang LN; Lee SHR; Yang JJ; Schmiegelow K
Leukemia; 2022 Jul; 36(7):1749-1758. PubMed ID: 35654820
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetic studies of thiopurine methyltransferase genotype-phenotype concordance and effect of methotrexate on thiopurine metabolism.
Zimdahl Kahlin A; Helander S; Wennerstrand P; Vikingsson S; Mårtensson LG; Appell ML
Basic Clin Pharmacol Toxicol; 2021 Jan; 128(1):52-65. PubMed ID: 32865889
[TBL] [Abstract][Full Text] [Related]
4. A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol.
Nicum S; Roberts C; Boyle L; Kopijasz S; Gourley C; Hall M; Montes A; Poole C; Collins L; Schuh A; Dutton SJ;
BMC Cancer; 2014 Dec; 14():983. PubMed ID: 25526776
[TBL] [Abstract][Full Text] [Related]
5. Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Levinsen M; Rosthøj S; Nygaard U; Heldrup J; Harila-Saari A; Jonsson OG; Bechensteen AG; Abrahamsson J; Lausen B; Frandsen TL; Weinshilboum RM; Schmiegelow K
Cancer Chemother Pharmacol; 2015 Jan; 75(1):59-66. PubMed ID: 25347948
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate promotes glucose uptake and lipid oxidation in skeletal muscle via AMPK activation.
Pirkmajer S; Kulkarni SS; Tom RZ; Ross FA; Hawley SA; Hardie DG; Zierath JR; Chibalin AV
Diabetes; 2015 Feb; 64(2):360-9. PubMed ID: 25338814
[TBL] [Abstract][Full Text] [Related]
7. Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.
Mikkelsen TS; Sparreboom A; Cheng C; Zhou Y; Boyett JM; Raimondi SC; Panetta JC; Bowman WP; Sandlund JT; Pui CH; Relling MV; Evans WE
J Clin Oncol; 2011 May; 29(13):1771-8. PubMed ID: 21444869
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate and erythro-9-(2-hydroxynon-3-yl) adenine therapy for rat adjuvant arthritis and the effect of methotrexate on in vivo purine metabolism.
Baggott JE; Morgan SL
Eur J Pharm Sci; 2007 Jun; 31(2):95-101. PubMed ID: 17408934
[TBL] [Abstract][Full Text] [Related]
9. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment.
Zaza G; Cheok M; Yang W; Panetta JC; Pui CH; Relling MV; Evans WE
Blood; 2005 Sep; 106(5):1778-85. PubMed ID: 15905191
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes.
Masson E; Zamboni WC
Clin Pharmacokinet; 1997 Apr; 32(4):324-43. PubMed ID: 9113440
[TBL] [Abstract][Full Text] [Related]
11. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.
Masson E; Relling MV; Synold TW; Liu Q; Schuetz JD; Sandlund JT; Pui CH; Evans WE
J Clin Invest; 1996 Jan; 97(1):73-80. PubMed ID: 8550853
[TBL] [Abstract][Full Text] [Related]
12. Nucleoside salvage and resistance to antimetabolite anticancer agents.
Fox M; Boyle JM; Kinsella AR
Br J Cancer; 1991 Sep; 64(3):428-36. PubMed ID: 1911182
[No Abstract] [Full Text] [Related]
13. Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts.
Bökkerink JP; Bakker MA; Hulscher TW; De Abreu RR; Schretlen ED; van Laarhoven JP; De Bruyn CH
Biochem Pharmacol; 1986 Oct; 35(20):3549-55. PubMed ID: 2429667
[TBL] [Abstract][Full Text] [Related]
14. 6-Mercaptopurine: cytotoxicity and biochemical pharmacology in human malignant T-lymphoblasts.
Bökkerink JP; Stet EH; De Abreu RA; Damen FJ; Hulscher TW; Bakker MA; van Baal JA
Biochem Pharmacol; 1993 Apr; 45(7):1455-63. PubMed ID: 7682415
[TBL] [Abstract][Full Text] [Related]
15. Effects of methotrexate on purine and pyrimidine metabolism and cell-kinetic parameters in human malignant lymphoblasts of different lineages.
Bökkerink JP; De Abreu RA; Bakker MA; Hulscher TW; van Baal JM; Schretlen ED; De Bruijn CH
Biochem Pharmacol; 1988 Jun; 37(12):2329-38. PubMed ID: 2455520
[TBL] [Abstract][Full Text] [Related]
16. [Biochemical and clinico-pharmacological aspects of antimetabolites in the treatment of leukemia].
Bökkerink JP; de Abreu RA; Lippens RJ; Schouten TJ; de Vaan GA
Tijdschr Kindergeneeskd; 1988 Apr; 56(2):55-60. PubMed ID: 3287684
[TBL] [Abstract][Full Text] [Related]
17. The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX).
Giverhaug T; Loennechen T; Aarbakke J
Gen Pharmacol; 1999 Oct; 33(4):341-6. PubMed ID: 10523073
[TBL] [Abstract][Full Text] [Related]
18. Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages.
Bökkerink JP; Bakker MA; Hulscher TW; De Abreu RA; Schretlen ED
Biochem Pharmacol; 1988 Jun; 37(12):2321-7. PubMed ID: 2455519
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
